SE503225C2 - Virus-antikroppskomplex för införing av virus i mammalieceller - Google Patents

Virus-antikroppskomplex för införing av virus i mammalieceller

Info

Publication number
SE503225C2
SE503225C2 SE9103183A SE9103183A SE503225C2 SE 503225 C2 SE503225 C2 SE 503225C2 SE 9103183 A SE9103183 A SE 9103183A SE 9103183 A SE9103183 A SE 9103183A SE 503225 C2 SE503225 C2 SE 503225C2
Authority
SE
Sweden
Prior art keywords
antibody
virus
viral
complex according
complex
Prior art date
Application number
SE9103183A
Other languages
English (en)
Swedish (sv)
Other versions
SE9103183L (sv
SE9103183D0 (sv
Inventor
Leif Lindholm
Sven Enerbaeck
Oerjan Strannegaard
Original Assignee
Leif Lindholm Konsult Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20384166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE503225(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leif Lindholm Konsult Ab filed Critical Leif Lindholm Konsult Ab
Priority to SE9103183A priority Critical patent/SE503225C2/sv
Publication of SE9103183D0 publication Critical patent/SE9103183D0/xx
Priority to CA002122613A priority patent/CA2122613C/en
Priority to PCT/SE1992/000745 priority patent/WO1993009221A1/en
Priority to ES92922980T priority patent/ES2180538T3/es
Priority to JP5508351A priority patent/JPH07502026A/ja
Priority to DE69232782T priority patent/DE69232782T2/de
Priority to US08/232,028 priority patent/US5695991A/en
Priority to EP92922980A priority patent/EP0614486B1/de
Priority to AT92922980T priority patent/ATE224442T1/de
Publication of SE9103183L publication Critical patent/SE9103183L/
Publication of SE503225C2 publication Critical patent/SE503225C2/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SE9103183A 1991-10-30 1991-10-30 Virus-antikroppskomplex för införing av virus i mammalieceller SE503225C2 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE9103183A SE503225C2 (sv) 1991-10-30 1991-10-30 Virus-antikroppskomplex för införing av virus i mammalieceller
AT92922980T ATE224442T1 (de) 1991-10-30 1992-10-28 Zielgerichtetes einbringen eines virus-vektors in säugetierzellen.
EP92922980A EP0614486B1 (de) 1991-10-30 1992-10-28 Zielgerichtetes Einbringen eines Virus-Vektors in Säugetierzellen.
ES92922980T ES2180538T3 (es) 1991-10-30 1992-10-28 Suministro dirigido de vector virico a celulas de mamiferos.
PCT/SE1992/000745 WO1993009221A1 (en) 1991-10-30 1992-10-28 Targeted delivery of virus vector to mammalian cells
CA002122613A CA2122613C (en) 1991-10-30 1992-10-28 Targeted delivery of virus vector to mammalian cells
JP5508351A JPH07502026A (ja) 1991-10-30 1992-10-28 ウイルス抗体複合体
DE69232782T DE69232782T2 (de) 1991-10-30 1992-10-28 Zielgerichtetes Einbringen eines Virus-Vektors in Säugetierzellen.
US08/232,028 US5695991A (en) 1991-10-30 1992-10-28 Targeted delivery of virus vector to mammalian cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9103183A SE503225C2 (sv) 1991-10-30 1991-10-30 Virus-antikroppskomplex för införing av virus i mammalieceller

Publications (3)

Publication Number Publication Date
SE9103183D0 SE9103183D0 (sv) 1991-10-30
SE9103183L SE9103183L (sv) 1993-05-01
SE503225C2 true SE503225C2 (sv) 1996-04-22

Family

ID=20384166

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9103183A SE503225C2 (sv) 1991-10-30 1991-10-30 Virus-antikroppskomplex för införing av virus i mammalieceller

Country Status (9)

Country Link
US (1) US5695991A (de)
EP (1) EP0614486B1 (de)
JP (1) JPH07502026A (de)
AT (1) ATE224442T1 (de)
CA (1) CA2122613C (de)
DE (1) DE69232782T2 (de)
ES (1) ES2180538T3 (de)
SE (1) SE503225C2 (de)
WO (1) WO1993009221A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820157B2 (en) 1997-04-10 2010-10-26 University Of Southern California Transgene delivering retrovirus targeting collagen exposed at site of tissue injury

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE503225C2 (sv) * 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
DE4311651A1 (de) * 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5753499A (en) * 1994-12-23 1998-05-19 New York University Viral vector complexes having adapters of predefined valence
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
CA2224907A1 (en) 1995-07-25 1997-02-13 Introgene B.V. Methods and means for targeted gene delivery
KR100353115B1 (ko) 1995-11-13 2003-01-06 다카라츠죠 가부시키가이샤 레트로바이러스를사용한표적세포내로의유전자도입방법
DE19605279A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
EP0927044A4 (de) * 1996-04-16 1999-09-08 Immusol Inc Gerichtete viral vektoren
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
DE19649645A1 (de) * 1996-11-29 1998-06-04 Hoechst Ag Mehrfach funktionelles Ligandensystem zur zielzellspezifischen Übertragung von Nukleotidsequenzen
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
AU7127798A (en) * 1997-04-18 1998-11-13 President And Fellows Of Harvard College Bifunctional polypeptides for cell-specific viral targeting
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
AU2662999A (en) * 1998-02-09 1999-08-23 Genzyme Corporation Nucleic acid delivery vehicles
US20060292121A1 (en) * 1998-04-29 2006-12-28 Hall Frederick L Retroviral vectors including modified envelope escort protein
US7078483B2 (en) 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
AU4070499A (en) 1998-04-30 1999-11-16 Cornell Research Foundation Inc. Adenoviral vectors with tandem fiber proteins
US6060316A (en) * 1998-06-09 2000-05-09 President And Fellows Of Harvard College Methods of targeting of viral entry
US6455314B1 (en) 1998-09-11 2002-09-24 Genvec, Inc. Alternatively targeted adenovirus
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
WO2001092549A2 (en) * 2000-05-31 2001-12-06 Genvec, Inc. Method and composition for targeting an adenoviral vector
DK1372708T3 (da) 2001-02-13 2008-10-20 Us Gov Sec Army Vaccine til transkutan immunisering mod rejsediarre
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US11266736B2 (en) 2008-04-17 2022-03-08 Vin De Bona Trading Company Pte Ltd Method of painting micro vesicles
EP2281033B1 (de) 2008-04-17 2014-10-15 Vin de Bona Trading Co Pte Modifizierung viraler hüllen nach deren freisetzung
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
IL270024B2 (en) 2017-04-22 2025-04-01 Immunomic Therapeutics Inc LAMP structures and their use in vaccination
KR20200016224A (ko) 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
EP3793595A1 (de) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Verbesserte lamp-konstrukte mit allergenen
JP2022551732A (ja) 2019-10-18 2022-12-13 イミュノミック セラピューティックス， インコーポレイテッド がん抗原を含む改良ｌａｍｐ構築物
EP4508071A1 (de) 2022-04-10 2025-02-19 Immunomic Therapeutics, Inc. Bicistronische lampenkonstrukte mit immunreaktionserhöhenden genen und verfahren zur verwendung davon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364934A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
US5428132A (en) * 1987-10-11 1995-06-27 United States Of America Conjugate and method for integration of foreign DNA into cells
WO1989007136A2 (en) * 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
JPH04504361A (ja) * 1989-04-05 1992-08-06 ノバセル　コーポレイション 感染性標的化複製―欠陥ビリオン
FR2649119A1 (fr) * 1989-06-30 1991-01-04 Centre Nat Rech Scient Procede de pilotage de retrovirus en utilisant des complexes bifonctionnels
AU648261B2 (en) * 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
WO1991004753A1 (en) * 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
CA2092323A1 (en) * 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
SE503225C2 (sv) * 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820157B2 (en) 1997-04-10 2010-10-26 University Of Southern California Transgene delivering retrovirus targeting collagen exposed at site of tissue injury
US8148509B2 (en) 1997-04-10 2012-04-03 University Of Southern California Transgene delivering retrovirus targeting collagen exposed at site of tissue injury
US8530441B2 (en) 1997-04-10 2013-09-10 University Of Southern California Transgene delivering retrovirus targeting collagen exposed at site of tissue injury

Also Published As

Publication number Publication date
EP0614486B1 (de) 2002-09-18
WO1993009221A1 (en) 1993-05-13
JPH07502026A (ja) 1995-03-02
DE69232782D1 (de) 2002-10-24
SE9103183L (sv) 1993-05-01
SE9103183D0 (sv) 1991-10-30
EP0614486A1 (de) 1994-09-14
US5695991A (en) 1997-12-09
ES2180538T3 (es) 2003-02-16
ATE224442T1 (de) 2002-10-15
CA2122613A1 (en) 1993-05-13
CA2122613C (en) 2003-08-19
DE69232782T2 (de) 2003-02-20

Similar Documents

Publication Publication Date Title
SE503225C2 (sv) Virus-antikroppskomplex för införing av virus i mammalieceller
FI110613B (fi) Kapsidia muodostava ja kysteiini-modifioitu kimeerinen MS2-vaippaproteiini
US6555367B1 (en) Complex of biotinylated viral vector and ligand for targeted gene delivery
US5547932A (en) Composition for introducing nucleic acid complexes into higher eucaryotic cells
JP4716350B2 (ja) 潜伏期膜タンパク質に対する抗体およびそれらの使用
Strand et al. Structural proteins of ribonucleic acid tumor viruses. Purification of envelope, core, and internal components.
US5166050A (en) Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
JP2528815B2 (ja) 多効果免疫性蛋白質
Singh et al. Expression of rabies glycoprotein and ricin toxin B chain (RGP–RTB) fusion protein in tomato hairy roots: a step towards Oral vaccination for rabies
US5981273A (en) Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
JPH06506583A (ja) ベクターとして修正された植物ウイルス
BE1000811A4 (fr) Anticorps monoclonaux, peptides et compositions les contenant, destinees au diagnostic et au traitement des infections par le virus hiv.
SK160391A3 (en) Recombinant proteine joining complex viral antigen hiv-1
JPS63501125A (ja) ヒトレトロウイルス遺伝子を発現する組換えワクチニアウイルス
CN105949316A (zh) 抗EGFRvIII嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
CN102690842B (zh) 一种表达人抗体全基因的重组腺病毒(rAdv)载体及其方法
US5364761A (en) Method for isolating a DNA encoding an autonomously replicating sequence
JPH02142737A (ja) 擬似狂犬病ウイルスワクチン
CN120518757B (zh) 一种聚乙二醇化多价抗西尼罗病毒单链抗体
Rammensee et al. Targeting cytotoxic T cells to antigen‐specific B lymphocytes
US20030044420A1 (en) Self antigen vaccines for treating B cell lymphomas and other cancers
Teramoto et al. Detection of novel murine mammary tumor viruses by interspecies immunoassays
Shinnick et al. Peptide-elicited protein-reactive antibodies in molecular biology and medicine
RU2217162C2 (ru) Вакцина против вирусных инфекций
CN120884692A (zh) 一种具有高效递送能力的复合型核酸类免疫增强物质及其制备方法和应用

Legal Events

Date Code Title Description
NUG Patent has lapsed